Navigation Links
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Date:9/9/2008

y, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:
-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to o
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the year ended December 31, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... did not provide the outcome management and investors ... at iCo Therapeutics", said Andrew Rae , ...
(Date:4/27/2015)... CAMBRIDGE, Massachusetts y HEIDELBERG ... - Molecular Health obtiene la patente para un nuevo ... Aborda una necesidad no cubierta en el ...   Molecular Health ha anunciado hoy que ha ... Receptor". Esta última patente apoya el descubrimiento de Molecular ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Dr. Robert ... and chemical toxicity carries implications for advancing the creation ... 28 at National University , the second-largest private, ... by Dr. Hanzlik, a professor at the University of ... and drug design, starts at 5 p.m. and takes ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... 26 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today ... at the Piper Jaffray 19th Annual,Health Care Conference at ... November 28, 2007 at 8:30 a.m. Eastern Time., ... on Lexicon,s,corporate website at http://www.lexpharma.com . An archived ...
... Income up $1,036,024, or 89%, for the nine months ended September 30, ... ... China, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai,Cactus Bio-tech Inc. (OTC Bulletin Board: ... cactus-based,consumer products, filed its quarterly report on SEC Form 10QSB on November,19, ...
... 26 PRA International,(Nasdaq: PRAI ), a ... Chambers has been named its senior vice president ... to human resources that will,help PRA grow," said ... and employment law in addition to strong tactical ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Chambers Joins PRA International as Senior Vice President of Human Resources 2
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... around the world think of dung, they think of Jim ... one of the world,s foremost authorities on animal dung, and ... got to laugh at this bizarre resource," says Mead, director ... anyone is keeping track, I suspect we have the largest ...
... Humans live in the midst of a seething, breathing ... and exotic, from the surface of the human skin, ... floors. Despite the powerful and pervasive role ... world remains a mystery. This is the subject of ...
... that drags large, heavy nets across the seafloor stirs up ... be seen from space. As a result of scientific ... sponges, fishes and other animals, bottom trawling has been banned ... Now satellite images show that spreading clouds of mud remain ...
Cached Biology News:Dung happens and helps scientists 2Dung happens and helps scientists 3Unexplored microbes hold incredible potential for science and industry 2Unexplored microbes hold incredible potential for science and industry 3Bottom trawling impacts, clearly visible from space 2Bottom trawling impacts, clearly visible from space 3
S-100A10 (H-80)...
... was derived from rabbit immunized with highly ... such as antibody fragments can be fused ... on phage using phagemid-based systems (1), rather ... Ph.D. libraries. Anti-M13 pIII Monoclonal Antibody can ...
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
Biology Products: